News

In May, Gilead Sciences secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its remdesivir to treat of hospitalised Covid-19 patients. Remdesivir is

The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, PEL, through one of its Affiliates, would acquire at closing a 100%

Following the approval from the drug regulator, Glenmark Pharmaceuticals has launched the generic version of oral antiviral drug Favipiravir under the brand name of FabiFlu. Favipiravir was developed

Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two

The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by

These single-use culture containers are designed by Saint-Gobain to provide a closed systems approach to cell culture and cell manufacturing, allowing for a seamless translation of bioprocesses from

The approval is said to confirm the Cosentyx efficacy in the treatment of axial spondyloarthritis (axSpA) disease spectrus. Cosentyx is claimed to be the first and only fully-human

In Neuville sur Saône in eastern France, Sanofi will build its Evolutive Vaccine Facility (EVF) with an investment of €490m over a five-year period. The vaccine production site

The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years.  IDEAYA has solved